Anti-BCMA novel therapies for multiple myeloma

被引：15
作者：
Sammartano, Vincenzo [1 ]
Franceschini, Marta [1 ]
Fredducci, Sara [1 ]
Caroni, Federico [1 ]
Ciofini, Sara [1 ]
Pacelli, Paola [1 ]
Bocchia, Monica [1 ]
Gozzetti, Alessandro [1 ,2 ]
机构：
[1] Univ Siena, Azienda Ospedaliero Univ Senese, Dept Med Surg & Neurosci, I-53100 Siena, Italy
[2] Univ Siena, Azienda Ospedaliero Univ Senese, Dept Med Surg & Neurosci, Viale Mario Bracci 16, I-53100 Siena, Italy
来源：
CANCER DRUG RESISTANCE | 2023年 / 6卷 / 01期
关键词：
Multiple myeloma; BCMA; belantamab; teclistamab; CART; CELL MATURATION ANTIGEN; NF-KAPPA-B; BELANTAMAB MAFODOTIN; RECEPTOR; SURVIVAL; OUTCOMES; APRIL; EFFICACY; DISEASE; MEMBER;
D O I：
10.20517/cdr.2022.138
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Recent advances in multiple myeloma therapy have increased the depth of response and ultimately survivals; however, the prognosis remains poor. The BCMA antigen is highly expressed in myeloma cells, thus representing a target for novel therapies. Several agents that target BCMA through different mechanisms, including bispecific T cell engagers drug conjugated to antibody and CAR-T cells, are now available or under development. Immunotherapies targeting BCMA have shown good results in efficacy and safety in multiple myeloma patients previously treated with several lines of therapy. This review will discuss the recent development of anti-BCMA targeted treatments in myeloma, with a special focus on currently available agents.
引用
收藏
页码：169 / 181
页数：13
相关论文
共 142 条
  • [1] Antibody-drug conjugates (ADCs) for cancer therapy: Strategies, challenges, and successes
    Abdollahpour-Alitappeh, Meghdad
    Lotfinia, Majid
    Gharibi, Tohid
    Mardaneh, Jalal
    Farhadihosseinabadi, Behrouz
    Larki, Pegah
    Faghfourian, Babak
    Sepehr, Koushan Sineh
    Abbaszadeh-Goudarzi, Kazem
    Abbaszadeh-Goudarzi, Ghasem
    Johari, Behrooz
    Zali, Mohammad Reza
    Bagheri, Nader
    [J]. JOURNAL OF CELLULAR PHYSIOLOGY, 2019, 234 (05) : 5628 - 5642
  • [2] T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma
    Ali, Syed Abbas
    Shi, Victoria
    Maric, Irina
    Wang, Michael
    Stroncek, David F.
    Rose, Jeremy J.
    Brudno, Jennifer N.
    Stetler-Stevenson, Maryalice
    Feldman, Steven A.
    Hansen, Brenna G.
    Fellowes, Vicki S.
    Hakim, Frances T.
    Gress, Ronald E.
    Kochenderfer, James N.
    [J]. BLOOD, 2016, 128 (13) : 1688 - 1700
  • [3] Idecabtagene vicleucel (ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma
    Anderson, Larry D., Jr.
    [J]. FUTURE ONCOLOGY, 2021, 18 (03) : 277 - 289
  • [4] Resistance against anti-CD19 and anti-BCMA CAR T cells: Recent advances and coping strategies
    Atilla, Pinar Ataca
    Atilla, Erden
    [J]. TRANSLATIONAL ONCOLOGY, 2022, 22
  • [5] BAFF selectively enhances the survival of plasmablasts generated from human memory B cells
    Avery, DT
    Kalled, SL
    Ellyard, JI
    Ambrose, C
    Bixler, SA
    Thien, M
    Brink, R
    Mackay, F
    Hodgkin, PD
    Tangye, SG
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2003, 112 (02) : 286 - 297
  • [6] Current Treatment for Multiple Myeloma
    Avigan, David
    Rosenblatt, Jacalyn
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (10) : 961 - 962
  • [7] Anti-BCMA Immunotoxins: Design, Production, and Preclinical Evaluation
    Bera, Tapan K.
    [J]. BIOMOLECULES, 2020, 10 (10) : 1 - 14
  • [8] Ciltacabtagene autoleucel, a B-cell maturation antigendirected chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
    Berdeja, Jesus G.
    Madduri, Deepu
    Usmani, Saad Z.
    Jakubowiak, Andrzej
    Agha, Mounzer
    Cohen, Adam D.
    Stewart, A. Keith
    Hari, Parameswaran
    Htut, Myo
    Lesokhin, Alexander
    Deol, Abhinav
    Munshi, Nikhil C.
    O'Donnell, Elizabeth
    Avigan, David
    Singh, Indrajeet
    Zudaire, Enrique
    Yeh, Tzu-Min
    Allred, Alicia J.
    Olyslager, Yunsi
    Banerjee, Arnob
    Jackson, Carolyn C.
    Goldberg, Jenna D.
    Schecter, Jordan M.
    Deraedt, William
    Zhuang, Sen Hong
    Infante, Jeffrey
    Geng, Dong
    Wu, Xiaoling
    Carrasco-Alfonso, Marlene J.
    Akram, Muhammad
    Hossain, Farah
    Rizvi, Syed
    Fan, Frank
    Lin, Yi
    Martin, Thomas
    Jagannath, Sundar
    [J]. LANCET, 2021, 398 (10297) : 314 - 324
  • [9] Targeted Therapy With Immunoconjugates for Multiple Myeloma
    Bruins, Wassilis S. C.
    Zweegman, Sonja
    Mutis, Tuna
    van de Donk, Niels W. C. J.
    [J]. FRONTIERS IN IMMUNOLOGY, 2020, 11
  • [10] Bu De-Xiu, 2018, Oncotarget, V9, P25764, DOI 10.18632/oncotarget.25359
12345678910